
|Videos|December 7, 2021
Dr. Armstrong on the efficacy of AR inhibitors in men with oligometastatic prostate cancer
Author(s)Urology Times staff
“Our data suggests that we shouldn’t just be relying on metastasis-directed therapy alone,” says Andrew J. Armstrong, MD, MSc.
Advertisement
In this video, Andrew J. Armstrong, MD, MSc, discusses the takeaways and further research associated with the study, “The efficacy of enzalutamide (Enza) plus androgen deprivation therapy (ADT) on oligometastatic hormone-sensitive prostate cancer: extended post hoc analysis of ARCHES,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Armstrong is a profession or medicine, surgery, and pharmacology and cancer biology at Duke University and a member of the Duke Cancer in Durham, North Carolina.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












